Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy

Legut, Mateusz, Cole, David ORCID: https://orcid.org/0000-0003-0028-9396 and Sewell, Andrew K. ORCID: https://orcid.org/0000-0003-3194-3135 2015. The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy. Cellular and Molecular Immunology 12 , pp. 656-668. 10.1038/cmi.2015.28

[thumbnail of Legut et al. 2015.pdf]
Preview
PDF - Published Version
Available under License Creative Commons Attribution.

Download (13MB) | Preview

Abstract

γδ T cells form an important part of adaptive immune responses against infections and malignant transformation. The molecular targets of human γδ T cell receptors (TCRs) remain largely unknown, but recent studies have confirmed the recognition of phosphorylated prenyl metabolites, lipids in complex with CD1 molecules and markers of cellular stress. All of these molecules are upregulated on various cancer types, highlighting the potential importance of the γδ T cell compartment in cancer immunosurveillance and paving the way for the use of γδ TCRs in cancer therapy. Ligand recognition by the γδ TCR often requires accessory/co-stimulatory stress molecules on both T cells and target cells; this cellular stress context therefore provides a failsafe against harmful self-reactivity. Unlike αβ T cells, γδ T cells recognise their targets irrespective of HLA haplotype and therefore offer exciting possibilities for off-the-shelf, pan-population cancer immunotherapies. Here, we present a review of known ligands of human γδ T cells and discuss the promise of harnessing these cells for cancer treatment.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Systems Immunity Research Institute (SIURI)
Subjects: Q Science > QR Microbiology > QR180 Immunology
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Uncontrolled Keywords: cancer; γδ T cells; immunotherapy; phosphoantigens; T cell receptor
Publisher: Nature Publishing Group
ISSN: 1672-7681
Funders: Wellcome Trust
Date of First Compliant Deposit: 30 March 2016
Date of Acceptance: 1 March 2015
Last Modified: 21 May 2023 07:32
URI: https://orca.cardiff.ac.uk/id/eprint/73071

Citation Data

Cited 86 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics